Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2019

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

C. Soussain
  • Function : Correspondent author
M. Blonski
  • Function : Author
K. Rezai
  • Function : Author
E. Boyle
  • Function : Author
R. Gressin
  • Function : Author
C. Moluçon-Chabrot
  • Function : Author
M.L. Lelez
  • Function : Author
A. Clavert
  • Function : Author
S. Coisy
  • Function : Author
S. Leruez
  • Function : Author
V. Touitou
  • Function : Author
A. El Yamani
  • Function : Author
K. Hoang-Xuan
  • Function : Author
Fichier principal
Vignette du fichier
S0959804919303508.pdf (730.53 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02182035 , version 1 (25-10-2021)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

C. Soussain, S. Choquet, M. Blonski, D. Leclercq, C. Houillier, et al.. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European Journal of Cancer, 2019, 117, pp.121-130. ⟨10.1016/j.ejca.2019.05.024⟩. ⟨hal-02182035⟩
42 View
681 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More